Results 81 to 90 of about 10,848 (199)

Neighborhood Socioeconomic Status and Short‐Term Functional Outcomes in Systemic Lupus Erythematosus

Arthritis Care &Research, Volume 78, Issue 11, Page 1640-1649, November 2026.
Objective Individuals with systemic lupus erythematosus (SLE) can accumulate functional status (FS) impairment. We evaluated the association between neighborhood socioeconomic disadvantage, as measured by the Area Deprivation Index (ADI), and FS in a national SLE sample.
Baljeet Rai, Jessica Fitzpatrick, Jing Li, Eric Roberts, Patricia Katz, Laura Plantinga, Gabriela Schmajuk, Jinoos Yazdany   +7 more
wiley   +1 more source

PDB: 3PP4, Cd20 in complex with obinutuzumab (313K, 40°C, 100 ns)

, 2023
Molecular Dynamics Simulations (100 nanoseconds) of Cd20 in complex with obinutuzumab (313K, 40 ...
Stan, Razvan
core   +1 more source

Age, Comorbidity Burden and Treatment Outcomes in Mature B‐Cell Lymphoproliferative Disorders: A Real‐World Study

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Introduction Treatment decisions in older patients with mature B‐cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.
Kevin Nasrinfar, Harrison Wildhaber, Rudolf Rohr, Gaëlle Rhyner Agocs, Urban Novak, Alessandra Curioni‐Fontecedro, Vérène Dougoud‐Chauvin   +6 more
wiley   +1 more source

Obinutuzumab jako nowa szansa terapeutyczna dla chorych na przewlekłą białaczkę limfocytową [PDF]

, 2015
Obinutuzumab (also known as GA101) is a humanized, glycoengineered type II monoclonal antibody targeted against CD20. Studies in animal models suggest that obinutuzumab shows superior efficacy, as compared with rituximab, by inducing direct cell death ...
Karczmarczyk, Agnieszka, Giannopoulos, Krzysztof; Zakład Hematoonkologii Doświadczalnej, Uniwersytet Medyczny w Lublinie, Lublin, Polska   +1 more
core   +1 more source

Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC

HemaSphere, Volume 10, Issue 11, November 2026.
Abstract The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based ...
Candida Vitale, Thomas Chatzikonstantinou, Christina Papangelou, Francesca Perutelli, Maria Chiara Montalbano, Giulia Bondielli, Elia Boccellato, Salem Alshemmari, Francesco Angotzi, Miguel Arguello‐Tomas, Tomas Arpas, Sandra Bašić‐Kinda, Sotiria Besikli‐Dimou, Łukasz Bołkun, Tomasz Buczek, Aleksandra Butrym, Katherine Chapis, Sofia Chatzileontiadou, Rosa Collado, Raul Cordoba Mascuñano, Lorenzo De Paoli, Marina Deodato, Maria Dimou, David Donaldson, Joanna Drozd‐Sokołowska, Salem Elias, Andrea Ferrario, Alberto Fresa, Anna Maria Frustaci, Rocío García‐Serra, Ajay Gogia, Isabel González‐Gascón‐y‐Marín, Vasko Graklanov, Maria Hryniewiecka, Zhu Huayuan, Elzbieta Iskierka‐Jażdżewska, Paula Jablonowska‐Babij, Ozren Jaksic, Elzbieta Kalicińska, Maria Kislova, Maya Koren‐Michowitz, Epameinondas Koumpis, Zuzana Kubová, Jorge Labrador, Pietro Lauzzana, Shai Levi, Francesca Martini, Mariia Mikhaleva, Eva Minga, Riccardo Moia, Elżbieta Morawiec‐Szymonik, Marta Morawska, Femke V. M. Mulder, Roberta Murru, Jacopo Olivieri, Ewa Paszkiewicz‐Kozik, Lata Rani, Josep Maria Roncero, Wojciech Salamon, Alessandro Sanna, Lydia Scarfò, Tereza Shokralla, Martin Šimkovič, Matevž Škerget, Emil Spasov, Antigoni Tranidou, Jagoda Tryc‐Szponder, Marzia Varettoni, Andrea Visentin, George Vrachiolias, David Waddell, Ewa Wasik‐Szczepanek, Kamil Wdowiak, Mateusz Wilk, Kamil Wiśniewski, Magdalena Witkowska, Mohamed Yassin, Seyma Yıldız, Klaudia Zielonka, Nil Albiol, Jennifer R. Brown, Benedetto Bruno, Mark Catherwood, Anastasia Chatzidimitriou, Michael Doubek, Gianluca Gaidano, Alessandro Gozzetti, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Krzysztof Jamroziak, Ioannis Kotsianidis, Luca Laurenti, Eugene Nikitin, Maria Papaioannou, Tomáš Papajik, Martin Špaček, Niki Stavroyianni, Josephine M. I. Vos, Tomasz Wróbel, Münci Yağcı, Arnon P. Kater, Matthew Davids, Petra Langerbeins, Kostas Stamatopoulos, Paolo Ghia, Marta Coscia   +106 more
wiley   +1 more source

Two Are Better than One: The Bi-Specific Antibody Mosunetuzumab Reveals an Improved Immune Response of Vγ9Vδ2 T Cells Targeting CD20 in Malignant B Cells in Comparison to the Mono-Specific Antibody Obinutuzumab

International Journal of Molecular Sciences
In treating cancer, immunotherapy has been established as a later-line treatment option in clinical practice. That includes stem cell transplantation, modified or activated immune cells, and antibodies directed against aberrant cells.
L. Marischen, Jürgen Fritsch, Jovana Ilic, Laura Wahl, Thomas Bertsch, Stefan Knop, A. Bold   +6 more
semanticscholar   +1 more source

STIM1 knock-down decreases the affinity of obinutuzumab for CD20 by altering CD20 localization to Triton-soluble membrane

, 2020
Obinutuzumab is thought to exert its effects through its high antibody-dependent cellular cytotoxicity (ADCC) via glyco-engineering of the Fc region. In addition, obinutuzumab causes direct binding-induced cell death (DCD) only by specifically binding to
김주영
core   +1 more source

PDB: 3PP4, Cd20 in complex with obinutuzumab (312K, 39°C, 100 ns)

, 2023
Molecular Dynamics Simulations (100 nanoseconds) of Cd20 in complex with obinutuzumab (312K, 39 ...
Stan, Razvan
core   +1 more source

Chronic Enterovirus Meningitis with Acute Hepatitis in a Patient with Chronic Lymphocytic Leukemia Treated with Venetoclax/Obinutuzumab: A Case Report

Case Reports in Oncology
Introduction: Enterovirus infection is typically asymptomatic with rapid host clearance. However, several cases of disseminated enterovirus infection in oncologic patients with obinutuzumab-induced hypogammaglobulinemia have been reported in ...
Kaya L. Curtis, Elizabeth M. Corley, Lee S. Gottesdiener, Erika M. Hissong, Alyson Kaplan, Lindsey E. Roeker, Rosy Priya L. Kodiyanplakkal   +6 more
doaj   +1 more source

Obinutuzumab in membranous nephropathy: a potential game-changer in treatment

Drugs in Context
Membranous nephropathy (MN) is a kidney disease characterized by thickening of the glomerular basement membrane due to immune complex deposition, often leading to nephrotic syndrome and potentially progressing to end-stage renal disease.
C. Sessa, Dario Galeano, Luca Zanoli, M. Delsante, G. Rossi, W. Morale   +5 more
semanticscholar   +1 more source